We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $1.92B
1-Year Est. Return 85.52%
This Fund
S&P 500
This Quarter Est. Return
-5.98%
1 Year Est. Return
+85.52%
3 Year Est. Return
+282.16%
5 Year Est. Return
+254.87%
10 Year Est. Return
+3,288.81%
AUM
$1.92B
AUM Growth
-$382M
Cap. Flow
-$115M
Cap. Flow %
-5.98%
Top 10 Hldgs %
45.28%
Holding
275
New
41
Increased
31
Reduced
101
Closed
38

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$24.8M
2
ASTH icon
Astrana Health
ASTH
+$16.6M
3
KSPI icon
Kaspi.kz JSC
KSPI
+$15.8M
4
LLY icon
Eli Lilly
LLY
+$15.2M
5
GPC icon
Genuine Parts
GPC
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 23.91%
2 Consumer Discretionary 7.8%
3 Financials 6.79%
4 Industrials 3.72%
5 Materials 3.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NEOV icon
176
NeoVolta
NEOV
$118M
$524K 0.03%
170,000
-23,798
-12% -$92.8K
FBRX icon
177
Forte Biosciences
FBRX
$1.12B
$518K 0.03%
20,000
-20,000
-50% -$576K
LGCY
178
Legacy Education Inc
LGCY
$148M
$501K 0.03%
40,000
-6,296
-14% -$74.3K
IDN icon
179
Intellicheck
IDN
$73.5M
$489K 0.03%
70,000
-6,895
-9% -$37.5K
TWIN icon
180
Twin Disc
TWIN
$335M
$482K 0.03%
31,967
GEOS icon
181
Geospace Technologies
GEOS
$91.6M
$479K 0.03%
39,252
CAMP icon
182
CAMP4 Therapeutics
CAMP
$164M
$476K 0.02%
108,000
-18,363
-15% -$87.2K
AIFC
183
AI Financial Corp
AIFC
$60.6M
$455K 0.02%
410,000
-70,308
-15% -$115K
OSS icon
184
One Stop Systems
OSS
$309M
$454K 0.02%
60,000
-30,253
-34% -$282K
GALT icon
185
Galectin Therapeutics
GALT
$229M
$453K 0.02%
162,484
ADMA icon
186
PUT
ADMA Biologics
ADMA
$1.92B
$451K 0.02%
50,000
ONL
187
Orion Office REIT
ONL
$148M
$447K 0.02%
208,134
RILY icon
188
BRC Group Holdings
RILY
$277M
$439K 0.02%
60,000
-20,000
-25% -$149K
RAIL icon
189
FreightCar America
RAIL
$275M
$438K 0.02%
55,000
-10,596
-16% -$120K
SRI icon
190
Stoneridge
SRI
$209M
$435K 0.02%
90,000
-11,765
-12% -$80.6K
LEN icon
191
Lennar Class A
LEN
$20.4B
$434K 0.02%
5,000
-60,500
-92% -$6.54M
INO icon
192
Inovio Pharmaceuticals
INO
$79.8M
$433K 0.02%
248,790
HRMY icon
193
PUT
Harmony Biosciences
HRMY
$2.04B
$412K 0.02%
+14,700
New +$482K
MBOT icon
194
Microbot Medical
MBOT
$115M
$410K 0.02%
170,000
-86,033
-34% -$192K
TAYD icon
195
Taylor Devices
TAYD
$175M
$399K 0.02%
7,000
-3,371
-33% -$259K
AGEN
196
Agenus
AGEN
$249M
$382K 0.02%
114,336
VERI icon
197
Veritone
VERI
$96.7M
$377K 0.02%
191,517
ISSC icon
198
Innovative Solutions & Support
ISSC
$342M
$370K 0.02%
18,000
-27,000
-60% -$626K
CHCI icon
199
Comstock Holding Companies
CHCI
$152M
$369K 0.02%
19,500
-14,627
-43% -$181K
RANI icon
200
Rani Therapeutics
RANI
$95.6M
$358K 0.02%
487,168

Similar funds

683 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, 683 Capital Management held 275 positions worth $1.92B, down 17% from $2.3B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

683 Capital Management withdrew a net $115M in Q1 2026, closing 38 positions and reducing 101 holdings. Its most notable exit was UWM Holdings, an estimated $30.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 22% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, 683 Capital Management opened a new position in Astrana Health worth $17.2M.

  • 683 Capital Management's largest Q1 2026 buy was Astrana Health: 700,000 shares worth $17.2M.
  • 683 Capital Management added most to Becton Dickinson in Q1 2026, an estimated $24.8M increase.
  • 683 Capital Management's biggest Q1 2026 reduction was GXO Logistics, cutting an estimated $10.6M.
  • 683 Capital Management fully exited UWM Holdings in Q1 2026, selling an estimated $30.9M.
  • 683 Capital Management's ten largest holdings make up 45% of its $1.92B portfolio in Q1 2026.
  • 683 Capital Management opened 41 new positions and closed 38 in Q1 2026.
  • 683 Capital Management's portfolio value fell 17% quarter-over-quarter to $1.92B.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.